Attached files
| file | filename |
|---|---|
| EX-99.2 - EX-99.2 - Xenon Pharmaceuticals Inc. | xene-ex992_9.htm |
| EX-99.1 - EX-99.1 - Xenon Pharmaceuticals Inc. | xene-ex991_6.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 15, 2018
XENON PHARMACEUTICALS INC.
(Exact name of Registrant as Specified in Its Charter)
|
Canada |
001-36687 |
98-0661854 |
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
200-3650 Gilmore Way Burnaby, British Columbia, Canada |
|
V5G 4W8 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (604) 484-3300
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
|
Item 8.01 |
Other Events |
On May 15, 2018, Xenon Pharmaceuticals Inc. (the “Company”) issued two press releases announcing a Phase 1 clinical update and supporting preclinical data for its product candidate XEN901 and interim Phase 1 data for its product candidate XEN1101.
Copies of the Company’s press releases are attached hereto as Exhibit 99.1 and 99.2 and are incorporated herein by reference.
|
Item 9.01 |
Financial Statements and Exhibits |
(d) Exhibits.
|
Exhibit Number |
Description |
|
99.1 99.2 |
Press Release issued by Xenon Pharmaceuticals Inc. dated May 15, 2018. Press Release issued by Xenon Pharmaceuticals Inc. dated May 15, 2018. |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Xenon Pharmaceuticals Inc. |
|
|
|
|
|
|
|
Date: May 15, 2018 |
|
By: |
/s/ Ian Mortimer |
|
|
|
|
Ian Mortimer |
|
|
|
|
President & Chief Financial Officer |